Do you want to read an article? Please log in or register.
Shorter Disease Duration is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease but Not Ulcerative Colitis
Inflammatory Bowel Disease
Related content
RECOMMENDED
Inflammatory Bowel Disease
Vedolizumab Efficacy, Safety, and Pharmacokinetics with Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients with Crohn's Disease or Ulcerative Colitis
★ 2
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
J Crohns Colitis.
Vermeire S, Lukáš M, Magro F, Adsul S, Lindner D, Rosario M, Roth J, Danese S
doi: 10.1093/ecco-jcc/jjaa027.
Inflammatory Bowel Disease
Short Disease Duration Is Associated With Increased Risk of Treatment Failure in Biologic-Treated Patients With Ulcerative Colitis
Inflamm Bowel Dis.
Nguyen NH, Kurnool S, Dulai PS, Boland BS, Sandborn WJ, Singh S
doi: 10.1093/ibd/izz276.
Inflammatory Bowel Disease
Immunological variables associated with clinical and endoscopic response to vedolizumab in patients with inflammatory bowel diseases
J Crohns Colitis.
Coletta M, Paroni M, Alvisi MF, De Luca M, Rulli E, Mazza S, Facciotti F, Lattanzi G, Strati F, Abrignani S, Fantini MC, Vecchi M, Geginat J, Caprioli F
doi: 10.1093/ecco-jcc/jjaa035.
Inflammatory Bowel Disease
Deep remission with vedolizumab in patients with moderately to severely active ulcerative colitis: a GEMINI 1 post hoc analysis
J Crohns Colitis.
Sandborn WJ, Colombel JF, Panaccione R, Dulai PS, Rosario M, Cao C, Barocas M, Lasch K
doi: 10.1093/ecco-jcc/jjy149.
RECOMMENDED
Inflammatory Bowel Disease
No Association Between Pseudopolyps and Colorectal Neoplasia in Patients With Inflammatory Bowel Diseases
doi: 10.1053/j.gastro.2018.11.067.
COMMENTED
Inflammatory Bowel Disease
Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis
Inflamm Bowel Dis.
Battat R, Dulai PS, Vande Casteele N, Evans E, Hester KD, Webster E, Jain A, Proudfoot JA, Mairalles A, Neill J, Singh S, Chang JT, Rivera-Nieves J, Sandborn WJ, Boland BS
doi: 10.1093/ibd/izy307.
Inflammatory Bowel Disease
Validation of the "German Inflammatory Bowel Disease Activity Index (GIBDI)": An Instrument for Patient-Based Disease Activity Assessment in Crohn's Disease and Ulcerative Colitis
Z Gastroenterol.
Hüppe A, Langbrandtner J, Häuser W, Raspe H, Bokemeyer B
doi: 10.1055/a-0605-4080.
Inflammatory Bowel Disease
Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review
BMC Gastroenterol.
Helwig U, Mross M, Schubert S, Hartmann H, Brandes A, Stein D, Kempf C, Knop J, Campbell-Hill S, Ehehalt R
doi: 10.1186/s12876-020-01332-w.
Inflammatory Bowel Disease
The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe
BMC Gastroenterol.
Armuzzi A, Tarallo M, Lucas J, Bluff D, Hoskin B, Bargo D, Cappelleri JC, Salese L, daCosta DiBonaventura M
doi: 10.1186/s12876-020-1164-0.